Literature DB >> 8958187

Exploitation of folate and antifolate polyglutamylation to achieve selective anticancer chemotherapy.

J J McGuire1, T Tsukamoto, B P Hart, J K Coward, T I Kalman, J Galivan.   

Abstract

Synthesis of poly(gamma-glutamate) metabolites of natural folates and antifolates is a critical process. Folypolyglutamates are essential for cell proliferation. Polyglutamates of glutamate (Glu)-containing antifolates are often critical for their cytotoxic action and are relevant to antifolate resistance. However, the role of polyglutamate synthesis in selectivity is less clear. We have undertaken a research program to further define the significance of polyglutamate metabolism and to devise ways to exploit this metabolism to achieve greater therapeutic selectivity in cancer chemotherapy. This article briefly reviews several approaches tested thus far. Inhibition of folypolyglutamate synthesis should lead to cell death. Current ornithine (Orn)-containing folate-based inhibitors of the enzyme responsible for their synthesis, folypolyglutamate synthetase (FPGS), are poorly transported, apparently because of interference by the protonated delta-amine. Replacement of Orn with 4, 4-difluoroOrn, the delta-amine of which has a much lower pKa and is thus less protonated at physiological pH, was explored. Since it is unclear how polyglutamylation contributes to selectivity, we explored generic means either to eliminate or to enhance polyglutamylation. The data indicate that substitution for Glu in an antifolate by some Glu analogs in which the gamma-COOH is either altered or replaced (e.g., gamma-tetrazole-Glu) leads to loss of both FPGS substrate activity and binding; antifolate target specificity is unchanged, while uptake is actually enhanced. Substitution of 3,3-difluoroGlu for Glu leads to enhanced polyglutamylation (although probably only to the diglutamate), retention of target specificity, and at least equal uptake. Comparative studies of the same antifolate containing different replacements for Glu, such as gamma-tetrazole-Glu (no polyglutamylation) or 3,3-difluoroGlu (enhanced polyglutamylation), will be useful in exploring the role and significance of polyglutamylation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958187     DOI: 10.1007/bf00194535

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  23 in total

Review 1.  TECHNIQUES FOR STUDY OF RESISTANCE TO FOLIC ACID ANTAGONISTS.

Authors:  J R BERTINO; G A FISCHER
Journal:  Methods Med Res       Date:  1964

2.  Folylpolyglutamate synthetase inhibition and cytotoxic effects of methotrexate analogs containing 2,omega-diaminoalkanoic acids.

Authors:  J J McGuire; P Hsieh; C T Franco; J R Piper
Journal:  Biochem Pharmacol       Date:  1986-08-01       Impact factor: 5.858

Review 3.  The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor.

Authors:  A L Jackman; R Kimbell; M Brown; L Brunton; K R Harrap; J M Wardleworth; F T Boyle
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

4.  gamma-Fluoromethotrexate: synthesis and biological activity of a potent inhibitor of dihydrofolate reductase with greatly diminished ability to form poly-gamma-glutamates.

Authors:  J Galivan; J Inglese; J J McGuire; Z Nimec; J K Coward
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

5.  DL-beta,beta-difluoroglutamic acid mediates position-dependent enhancement or termination of pteroylpoly(gamma-glutamate) synthesis catalyzed by folylpolyglutamate synthetase.

Authors:  J J McGuire; B P Hart; W H Haile; M S Rhee; J Galivan; J K Coward
Journal:  Arch Biochem Biophys       Date:  1995-08-20       Impact factor: 4.013

6.  Synthesis and biological activity of folic acid and methotrexate analogues containing L-threo-(2S,4S)-4-fluoroglutamic acid and DL-3,3-difluoroglutamic acid.

Authors:  B P Hart; W H Haile; N J Licato; W E Bolanowska; J J McGuire; J K Coward
Journal:  J Med Chem       Date:  1996-01-05       Impact factor: 7.446

7.  Synthesis and biological evaluation of DL-4,4-difluoroglutamic acid and DL-gamma,gamma-difluoromethotrexate.

Authors:  T Tsukamoto; T Kitazume; J J McGuire; J K Coward
Journal:  J Med Chem       Date:  1996-01-05       Impact factor: 7.446

Review 8.  The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694.

Authors:  A L Jackman; W Gibson; M Brown; R Kimbell; F T Boyle
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

9.  DL-3,3-difluoroglutamate: an enhancer of folylpolyglutamate elongation.

Authors:  J J McGuire; W H Haile; P Bey; J K Coward
Journal:  J Biol Chem       Date:  1990-08-25       Impact factor: 5.157

10.  Folate analogues. 34. Synthesis and antitumor activity of non-polyglutamylatable inhibitors of dihydrofolate reductase.

Authors:  A Abraham; J J McGuire; J Galivan; Z Nimec; R L Kisliuk; Y Gaumont; M G Nair
Journal:  J Med Chem       Date:  1991-01       Impact factor: 7.446

View more
  1 in total

Review 1.  A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight.

Authors:  Christine R Cuthbertson; Zahra Arabzada; Armand Bankhead; Armita Kyani; Nouri Neamati
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.